Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

Inclusion Criteria: * Clinical diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT) in at least one eye. * Non-study eye: Intraocular pressure (IOP) able to be controlled with no pharmacologic therapy or on the study medicine alone. * Willing to discontinue the use of all other ocular hypotensive medications prior to receiving study medication and for the entire course of the study. * Able to follow instructions, self instill study article, and attend all study visits. * Best-corrected Snellen visual acuity of 20/200 or better in each eye. * Sign Ethics Committee reviewed and approved informed consent form. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Known medical history of allergy, hypersensitivity or poor tolerance to any component of the preparations used in this study. * Any abnormality preventing applanation tonometry in either eye. * Dry eye previously or currently being treated with punctal plugs, punctal cautery, Restasis®, or topical ocular corticosteroids. * Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye. * Intraocular conventional or laser surgery \>3 months prior to consent. * Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment. * Progressive retinal or optic nerve disease from any cause. * Use of any systemic medications known to affect IOP which have not been on a stable course for at least 7 days prior to Screening or an anticipated change in dosage during the course of the study. * Any clinically significant, serious, or severe medical condition. * Women of childbearing potential who are pregnant, lactating, or not using reliable means of birth control. * Participation in any other study within 30 days prior to Screening. * Use of any systemic (oral), injectable or topical steroids. * Other protocol-defined exclusion criteria may apply.